Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Prioritisation programme

Prioritisation programme

Decision

Decision

Showing 1 to 25 of 25

TitlePrioritisation programmeDecisionDecision date
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]None selectedNot selected
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106None selectedNot selected
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]None selectedNot selected
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]None selectedNot selected
Lebrikizumab for treating atopic dermatitis in children [TSID12133]None selectedNot selected
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]None selectedNot selected
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353None selectedNot selected
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]None selectedNot selected
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]None selectedNot selected
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]None selectedn/a
Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]None selectedNot selected
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994None selectedNot selected
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]None selectedNot selected
Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]None selectedNot selected
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in childrenNone selectedNot selected
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]None selectedNot selected
Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]None selectedNot selected
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]None selectedNot selected
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]None selectedNot selected
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]None selectedNot selected
Dupilumab for children with severe atopic dermatitis [TSID10434]None selectedNot selected
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]None selectedNot selected
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]None selectedFurther information required
Moor LDLS-BI for assessing burn depth and healing potential in children and adultsNone selectedNot selected
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]None selectedNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All